Biosion, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biosion, Inc. - overview
Established
2017
Location
Nanjing, Jiangsu, China
Primary Industry
Biotechnology
About
Established in 2017 and based in Nanjing, China, Biosion, Inc. is a biotechnology company that engages in the research and development and production of antibody drugs for tumors and immune diseases. Dr. Mingjiu Chen, the company's founder, used to work as a senior scientist at AbbVie.
It has oversea offices in the US and Australia. In April 2023, it raised series B+ funding from new investors Ruiying Holdings, Harmony Venture, and an individual investor. The company engages in the research and development and production of antibody drugs for immune and oncologic diseases. It self-developed the H3 antibody discovery platform, SynAb collaborative antibody discovery platform, and SynTracer antibody endocytosis screening platform.
The H3 antibody discovery platform provides high-throughput, high-capacity screening services for drug molecules. It developed mono and bi-specific protein therapeutics, antibody-drug conjugates, and macrophage reprogramming agents for oncology and immunology. Its main product, BSI-045B (anti-TSLP mAb), is in phase II for severe asthma and phase-I for atopic dermatitis. n August 2025, Biosion, Inc.
closed a venture funding from new investor Huangpu Biomedical Investment, Guangzhou Xinxing Fund, and Shenzhen Oriental Huisheng Capital Management.
Current Investors
Renhe Capital, Lapam Capital, Kaiyuan Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Bioinformatics, Pharmaceutical Research & Development
Website
www.biosion.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.